To report the long-term outcomes of a pediatric patient with recurrent Wilms tumor treated with BRAF/MEK inhibition, focusing on the implications of targeted therapy.
Key Findings:
The patient remains disease-free two years after discontinuation of targeted therapy, marking a significant milestone in treatment outcomes.
Targeted therapy was well tolerated with only minor adverse effects, indicating a favorable safety profile.
This case represents the first report of long-term survival after targeted therapy for multiply relapsed BRAF V600E Wilms tumor, suggesting potential for broader application.
Interpretation:
The successful use of precision-targeted therapy in this case suggests potential for broader application in similar cases of relapsed Wilms tumor.
Limitations:
This is a single case report, limiting generalizability and necessitating further studies.
Long-term effects of BRAF/MEK inhibition in pediatric patients remain unclear, highlighting the need for more extensive research.
Conclusion:
Targeted therapy with BRAF/MEK inhibitors may offer a promising treatment avenue for recurrent Wilms tumor, warranting further investigation.
